Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor
antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be
better described as a selective adrenoreceptor modulator. It has antihypertensive and
antianginal properties and is indicated for those uses in various countries around the world.
In the United States, however, the proposed indication for this drug will be for the treatment
of vascular type Ehlers–Danlos syndrome, a rare connective tissue disorder characterized …